Kineta (Reverse Merger With Yumanity Therapeutics)

company

About

Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$33.59M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
11 - 50
Operating Status
Active

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$33.59M
Kineta (Reverse Merger With Yumanity Therapeutics) has raised a total of $33.59M in funding over 2 rounds. Their latest funding was raised on Dec 15, 2020 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 15, 2020 Series Unknown $33.59M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Kineta (Reverse Merger With Yumanity Therapeutics) is funded by 2 investors. Maven Investment Partners US and Stonepine Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Maven Investment Partners US Series Unknown
Stonepine Capital Series Unknown